Paskins, Z, Whittle, R, Abdul Sultan, A, Muller, S, Blagojevic-Bucknall, M, Helliwell, T, Packham, J, Hider, S, Roddy, E and Mallen, CD (2018) Risk of fragility fracture among patients with late-onset psoriasis: a United Kingdom population-based study. Osteoporosis International, 29 (7). pp. 1659-1664. ISSN 0937-941X

[img] Text
Z Paskins - Risk of fragility fracture among patients with late onset psoriasis.pdf - Accepted Version
Restricted to Repository staff only until 24 March 2019.
Available under License Creative Commons Attribution Non-commercial.

Download (383kB)

Abstract

This study aimed to examine fracture risk in patients with late-onset psoriasis. A cohort study was conducted using primary care records from the Clinical Practice Research Datalink. Psoriasis patients had a 10% increased risk of fracture compared to matched controls (hazard ratio (HR) = 1.10; 95% confidence interval (CI) 1.04, 1.16).

This study aimed to examine fracture risk in patients with late-onset psoriasis and investigate the effect of methotrexate on fracture risk.

A cohort study was conducted using primary care records from the UK-based Clinical Practice Research Datalink. Individuals aged 40 years and over, with incident (new onset) diagnoses of psoriasis, were identified from 1990 to 2004 and followed up until 2015. For each exposed individual, up to four age-, gender-, and practice-matched controls were randomly selected. Incidence rates of fragility fracture (hip, vertebral, spine, radius or unspecified site) per 10,000 person-years were calculated and hazard rates were compared to the unexposed using Cox regression models. The risk of fracture was also estimated, within the exposed group for patients receiving/not receiving methotrexate.

Twenty-four thousand two hundred nineteen patients with psoriasis and 94,820 controls were identified. The absolute rate of fracture in psoriasis patients was 58 per 10,000 person-years (95% CI 55, 61) and 53 per 10,000 person-years in the matched controls (CI 52, 54). Psoriasis patients had a 10% increased risk of fracture compared to their matched controls (HR = 1.10; 95% CI 1.04, 1.16). Methotrexate use was not associated with increased risk (HR = 0.91; 95% CI 0.72, 1.15).

Identifying additional clinical factors associated with increased fracture risk is important in improving fracture risk stratification. Further work is needed to determine the relationship between age of onset of psoriasis and fracture risk, explore causative explanations, and identify if existing fracture risk stratification tools underestimate fracture risk in patients with psoriasis.

Item Type: Article
Additional Information: “This is a post-peer-review, pre-copyedit version of an article published in Osteoporosis International. The final authenticated version is available online at: http://dx.doi.org/10.1007/s00198-018-4491-z”.
Uncontrolled Keywords: psoriasis, fracture, osteoporosis, methotrexate
Subjects: R Medicine > R Medicine (General)
R Medicine > RA Public aspects of medicine
R Medicine > RC Internal medicine > RC925 Diseases of the musculoskeletal system
Divisions: Faculty of Medicine and Health Sciences > Primary Care Health Sciences
Depositing User: Symplectic
Date Deposited: 26 Mar 2018 10:03
Last Modified: 30 Jul 2018 15:28
URI: http://eprints.keele.ac.uk/id/eprint/4642

Actions (login required)

View Item View Item